Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $90.3952W HIGH $212.75
Volume
1.32 M
Value Traded
485.45 M
Short % Float
5.02%
-9.22%Week
-21.68%1 Month
-12.74%3 Month
-34.84%6 Month
+299.55%5 Year
-33.6%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
21.99 B
EPS (TTM)
-4.01
P/E Ratio
-
Ent. Value
21.50 B
Total Shares
218.47 M
Float Shares
215.15 M
Insiders
1.48%
Institutions
102.74%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
INSM Catalyst Timeline
Dated clinical, regulatory and corporate events for Insmed Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Insmed Incorporated
766Total events
18Upcoming
179Tier-1 (high impact)
2010 to 2035Coverage
Upcoming catalysts 2
Event history 50
▲FDA Filing AcceptedArikayceApprovedRegulatory Filing
FDA accepts Insmed's sNDA for ARIKAYCE for MAC lung disease
Mycobacterium avium complex (MAC) lung diseasesource ↗
▲Priority ReviewArikayceApprovedRegulatory Filing
FDA grants Priority Review to ARIKAYCE sNDA
Mycobacterium avium complex (MAC) lung diseasesource ↗
◆Poster PresentationPresentation
Treatment Patterns and Healthcare Resource Utilization Associated With Bronchiectasis and Pulmonary Exacerbations in Spain
Bronchiectasissource ↗
◆Oral PresentationArikayceApprovedPresentation
Late-Breaking Abstract: Microbiologic Outcomes and Recurrence in Patients With Newly Diagnosed Mycobacterium avium Complex Lung Disease (MACLD) in the Phase 3b ENCORE Trial
Mycobacterium avium complex (MAC) lung diseasesource ↗
◆Poster PresentationPresentation
COMPERA 2.0 Risk Assessment of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH): A Post Hoc Analysis of a Phase 2 Study
Pulmonary Arterial Hypertension (PAH)source ↗
◆Poster PresentationBRINSUPRIApprovedPresentation
Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacteria (NTM) Infection: A Post Hoc Analysis of the ASPEN Trial
Non-Cystic Fibrosis Bronchiectasis (NCFB) with history of NTM infectionsource ↗
◆Poster PresentationPresentation
Quantifying the Psychosocial Impact of Exacerbations in Bronchiectasis: A European Patient-Centered Study
Bronchiectasissource ↗
▲FDA ApprovalBRINSUPRIApprovedFDA Decision
MHLW approval of BRINSUPRI for NCFB in Japan
non-cystic fibrosis bronchiectasis (NCFB)source ↗
▲EU ApprovalBRINSUPRIApprovedEx-US Regulatory
MHLW approval of BRINSUPRI for NCFB in Japan
non-cystic fibrosis bronchiectasissource ↗
▲Other Regulator MilestoneBRINSUPRIApprovedEx-US Regulatory
BRINSUPRI approved by Japan's MHLW for NCFB
non-cystic fibrosis bronchiectasis (NCFB)source ↗
▲Quarterly UpdateCorporate
Company raises peak revenue estimate for three lead programs to >$14B total
▲Quarterly UpdateBRINSUPRIApprovedCorporate
Company raises 2026 BRINSUPRI revenue guidance to $1.25B-$1.40B
non-cystic fibrosis bronchiectasissource ↗
●Quarterly UpdateArikayceApprovedCorporate
Company reiterates 2026 ARIKAYCE revenue guidance of $450M-$470M
MAC lung diseasesource ↗
●Enrollment UpdateTrial
Enrollment ongoing in PALM-ILD trial of TPIP
pulmonary hypertension associated with interstitial lung diseasesource ↗
●Enrollment UpdateINS1201Trial
Enrollment ongoing in Phase 1 ASCEND study of INS1201
Duchenne muscular dystrophysource ↗
●Enrollment UpdateINS1202Trial
Enrollment ongoing in Phase 1 ARMOR study of INS1202
amyotrophic lateral sclerosissource ↗
◆IND SubmissionIND
Company anticipates submitting 1-2 INDs per year from preclinical programs
▲Full ResultsClinical Data
Positive 12-month data from OLE study of TPIP in PAH
pulmonary arterial hypertensionsource ↗
▲Trial InitiationTrial
Initiation of Phase 3 PALM-PAH trial of TPIP in PAH
pulmonary arterial hypertensionsource ↗
●Oral PresentationPresentation
Investor call to discuss TPIP OLE study results
pulmonary arterial hypertensionsource ↗
●sNDA SubmissionArikayceApprovedRegulatory Filing
sNDA submitted to FDA for ARIKAYCE in newly diagnosed MAC lung disease
MAC lung diseasesource ↗
◆PMDA MilestoneArikayceApprovedEx-US Regulatory
Planned submission to PMDA for label expansion in Japan
MAC lung diseasesource ↗
▲Long Term DataClinical Data
Positive 12-month data from OLE study of TPIP in PAH reported
pulmonary arterial hypertensionsource ↗
◆Trial InitiationINS1033Trial
Phase 1 trial of INS1033 in healthy volunteers planned for Q3 2026
rheumatoid arthritissource ↗
▲Partnership / LicenseBrensocatibApprovedCorporate
EMBARC announces intention to collaborate with Insmed on interventional study of brensocatib
bronchiectasissource ↗
◆Management ChangeCorporate
Appointment of Samuele Butera as Senior Vice President, General Manager, Global Respiratory
◆Oral PresentationPresentation
Insmed management to present at 2026 Goldman Sachs Annual Global Healthcare Conference
▲Partnership / LicenseBrensocatibApprovedCorporate
EMBARC collaboration to conduct three-year study of brensocatib
bronchiectasissource ↗
●Management ChangeCorporate
Samuele Butera appointed SVP, General Manager, Global Respiratory
◆Poster PresentationPresentation
Data highlighting disease burden in PH-ILD at ATS 2026
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
◆Oral PresentationBRINSUPRIApprovedPresentation
Post-hoc analysis from Phase 3 ASPEN trial of BRINSUPRI at ATS 2026
non-cystic fibrosis bronchiectasis (NCFB)source ↗
◆Poster PresentationBRINSUPRIApprovedPresentation
Real-world experience data in NCFB patients at ATS 2026
non-cystic fibrosis bronchiectasis (NCFB)source ↗
◆Poster PresentationPresentation
Pharmacokinetic analysis of TPIP at ATS 2026
pulmonary hypertension associated with interstitial lung disease (PH-ILD)source ↗
◆Late-BreakerArikayceApprovedPresentation
Late-breaking ARIKAYCE results from Phase 3b ENCORE study at ATS 2026
Mycobacterium avium complex (MAC) lung infectionsource ↗
▲Primary Endpoint MetArikayceApprovedClinical Data
Phase 3b ENCORE study of ARIKAYCE met primary and all multiplicity-controlled secondary culture conversion endpoints
MAC lung diseasesource ↗
▲Partnership / LicenseCorporate
Insmed provides independent research grant to ATS for bronchiectasis diagnosis quality initiative
bronchiectasissource ↗
▼Primary Endpoint MissedBrensocatibApprovedClinical Data
Phase 2b CEDAR study did not meet primary or secondary efficacy endpoints
hidradenitis suppurativasource ↗
▼Program DiscontinuationBrensocatibApprovedCorporate
Insmed will discontinue development program of brensocatib in HS
hidradenitis suppurativasource ↗
▲Trial InitiationTrial
Phase 3 PALM-PAH study of TPIP initiated
pulmonary arterial hypertension (PAH)source ↗
◆Topline ReadoutArikayceApprovedClinical Data
Topline data from Phase 3 ENCORE study of ARIKAYCE anticipated in March or April 2026
newly diagnosed or recurrent MAC lung diseasesource ↗
◆Topline ReadoutBrensocatibApprovedClinical Data
Topline data from Phase 2b CEDAR study of brensocatib in HS anticipated in Q2 2026
hidradenitis suppurativasource ↗
▲Topline ReadoutArikayceApprovedClinical Data
Positive topline results from Phase 3b ENCORE study of ARIKAYCE in MAC lung disease
MAC lung diseasesource ↗
▲Primary Endpoint MetArikayceApprovedClinical Data
Primary endpoint met in ENCORE study
MAC lung diseasesource ↗
Past FDA Catalysts and PDUFA Decisions
How INSM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-06 | Treprostinil palmitil inhalation powder (TPIP) | Phase 2 data presentation | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C58 / 100
Pipeline Score
$2.0B
Pipeline Value
$4.5B
Commercial Value
Richly Valued
Valuation Signal
9
Drugs Scored
0.1x
rNPV / MCap
Top 9%
Mid Cap(rank 60 of 658)
Percentile Rank
Insmed Incorporated carries a moderate pipeline score (58/100), with $2.4B risk-adjusted pipeline value, led by OpSCF in Atopic Dermatitis (Phase 2), across $76B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $1.1B x 4.0 = $4.5B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| BRINSUPRI | $690M | - | - |
| ARIKAYCE | $448M | $398M | +12.5% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OpSCF Monoclonal antibodyCompletedNCT06101823 | Atopic Dermatitis | Phase 2 | COMPLETED | 50 | Aug 18, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every INSM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| brensocatib BreakthroughPriority | hidradenitis suppurativa | Phase 2b | 2026-04-07 | 10 mg reduction: 45.5%; 40 mg reduction: 40.3%; placebo reduction: 57.1%Read More | Insmed Provides Clinical Update on Phase 2b CEDAR Study -Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program- -Safety Was Consistent with Previous Studies and No New Safety SignRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Brennan David RDirector | Sell | -25,000 39,238 held | $124.00 | 09/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in INSM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 4.7 % (-32.9 %) | 937.84 M | 8.80 M | 18.53% ( 1.38 M) |
INSM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How INSM ranks across every disease it competes in
Competitive Position is a premium feature
See how INSM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialINSM News
INSM▼ -6.6%on this news
Insmed Announces CFO Transition
Insmed Incorporated announced the upcoming resignation of CFO Sara Bonstein, effective October 30, 2026, after nearly seven years. The company expressed gratitude for her contributions, particularly in raising significant capital. Insmed reaffirmed its full-year financial guidance and plans to hold a conference call to discuss third-quarter results on October 29, 2026.
Read more →INSMFDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
Insmed's Supplemental New Drug Application for ARIKAYCE has been accepted by the FDA for Priority Review, targeting a decision date of January 28, 2027. This application is based on positive outcomes from the Phase 3b ENCORE study, which demonstrated significant improvements in treating Mycobacterium avium complex lung disease. If approved, ARIKAYCE could be available to patients earlier in their disease progression.
Read more →INSMInsmed Expands Community Impact During Fifth Annual Global Day of Good
Insmed Incorporated celebrated its fifth annual Global Day of Good, with over 1,350 employees volunteering across the U.S., Europe, and Japan. This year's event marked the largest participation yet, benefiting more than 50 nonprofit organizations. Employees engaged in various activities, including STEM education support and environmental initiatives, reinforcing the company's commitment to community service.
Read more →INSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated announced the granting of inducement awards to 128 new employees as part of its 2025 Inducement Plan. The awards include restricted stock units and stock options, designed to attract talent in compliance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term and a four-year vesting schedule.
Read more →INSMInsmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026
Insmed Incorporated announced that five abstracts from its respiratory portfolio will be presented at the European Respiratory Society Congress 2026. Notable highlights include late-breaking results from the Phase 3b ENCORE study on ARIKAYCE for Mycobacterium avium complex lung disease. The presentations aim to address significant challenges in treating respiratory diseases and improve patient outcomes.
Read more →INSMInsmed to Present at September 2026 Investor Conferences
Insmed Incorporated announced its participation in two upcoming investor conferences in September 2026. The 12th Annual Cantor Fitzgerald Global Healthcare Conference will take place on September 9, followed by the 24th Annual Morgan Stanley Global Healthcare Conference on September 14. Both events will be webcasted live and archived for 30 days.
Read more →INSMBRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
Insmed's BRINSUPRI (brensocatib) has been approved by Japan's Ministry of Health for treating non-cystic fibrosis bronchiectasis (NCFB) in patients aged 12 and older. This marks a significant advancement as it is the first and only approved therapy for NCFB in Japan. The approval is based on positive results from the Phase 3 ASPEN study, which demonstrated substantial benefits in reducing exacerbations and preserving lung function.
Read more →INSM▲ +33.9%on this news
Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
Insmed Incorporated reported strong financial results for the second quarter of 2026, with total revenues of $425.5 million, driven by significant growth in BRINSUPRI and ARIKAYCE. The company raised its revenue guidance for BRINSUPRI and increased peak revenue estimates for its lead programs. Additionally, positive data from ongoing studies for TPIP in pulmonary arterial hypertension (PAH) was highlighted. Despite these successes, Insmed reported a net loss and rising expenses.
Read more →INSMInsmed to Host Second-Quarter 2026 Financial Results Conference Call on Thursday, August 6, 2026
Insmed Incorporated announced it will release its second-quarter 2026 financial results on August 6, 2026. A conference call for investors will take place at 8:00 a.m. ET on the same day, providing financial insights and business updates. Interested parties can participate via phone or through a live webcast.
Read more →INSMInsmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension
Insmed announced positive 12-month data from the open-label extension study of treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH). The study showed sustained improvements across all secondary efficacy measures, with no new safety signals. Patients switching from placebo to TPIP achieved similar clinical benefits, reinforcing TPIP's potential as a leading treatment option. Insmed is advancing to a Phase 3 study.
Read more →INSMEMBARC Announces Its Intention to Collaborate with Insmed on Landmark Interventional Study Evaluating Disease Modification Potential of Brensocatib in Bronchiectasis
EMBARC has announced a collaboration with Insmed to conduct a landmark study on brensocatib's potential to modify bronchiectasis disease progression. The long-term, open-label study will enroll approximately 3,000 patients across Europe, aiming to evaluate the drug's effects on lung function decline and exacerbation frequency. This research builds on previous trial data and seeks to determine if earlier intervention can significantly change disease outcomes.
Read more →INSMInsmed Appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
Insmed has appointed Samuele Butera as Senior Vice President and General Manager of Global Respiratory. With over two decades of experience in commercial leadership, Butera will oversee Insmed's Respiratory Therapeutic Area. His previous roles include significant positions at Johnson & Johnson and Novartis, where he led successful product launches and expansions.
Read more →INSMInsmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to...
Insmed Incorporated (Nasdaq: INSM) has granted inducement awards to 103 new employees under its 2025 Inducement Plan, as part of Nasdaq Listing Rule 5635(c)(4). The awards include 97,091 restricted stock units and options to purchase 12,850 shares of common stock, all of which have a specific vesting schedule designed to enhance employee retention. This initiative underscores Insmed's commitment to attracting talent to support its ongoing development of innovative therapies for serious diseases.
Read more →INSMInsmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
Insmed Incorporated will present at the 2026 Goldman Sachs Annual Global Healthcare Conference on June 9, 2026. The event will be webcast live and archived for 30 days. Insmed focuses on delivering innovative therapies for serious diseases and has been recognized as a top employer in the biopharmaceutical sector.
Read more →INSM▼ -23.4%on this news
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
Insmed reported a strong financial performance for Q1 2026, with total revenues of $306 million. BRINSUPRI revenues increased significantly, while ARIKAYCE also showed modest growth. The company reiterated its revenue guidance for both products and announced the initiation of a Phase 3 study for TPIP. Positive results from the ENCORE study further bolster Insmed's growth prospects.
Read more →INSM▼ -23.4%on this newsshared move
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
Insmed has partnered with Ty Pennington to launch the Suspect Bronchiectasis initiative, aimed at increasing awareness and proper diagnosis of bronchiectasis. This chronic lung disease often goes unrecognized due to symptom overlap with conditions like COPD and asthma. The initiative encourages patients with unresolved respiratory issues to consult pulmonologists for further testing.
Read more →INSM▲ +5.1%on this news· ran to -21% by day 3shared move
Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
Insmed Incorporated will present six abstracts from its respiratory portfolio at the ATS 2026 conference, including late-breaking results from the Phase 3b ENCORE study on ARIKAYCE. The conference will highlight the company's commitment to addressing serious pulmonary conditions and improving bronchiectasis diagnosis through an independent research grant. The findings aim to showcase the potential of ARIKAYCE in treating Mycobacterium avium complex lung disease.
Read more →INSMInsmed to Present at May 2026 Investor Conferences
Insmed Incorporated announced its participation in two upcoming investor conferences in May 2026. The BofA Securities Healthcare Conference will take place in Las Vegas, while the RBC Capital Markets Global Healthcare Conference will be held in New York City. Both events will be webcast live, allowing broader access to the company's updates.
Read more →INSMInsmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
Insmed Incorporated will release its first-quarter 2026 financial results on May 7, 2026. The company will host a conference call at 8:00 a.m. ET to discuss these results and provide a business update. Interested parties can participate by phone or via a live webcast on Insmed's website.
Read more →INSMInsmed Provides Clinical Update on Phase 2b CEDAR Study -Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program- -Safety Was Consistent with Previous Studies and No New Safety Sign
Insmed Incorporated announced that the Phase 2b CEDAR study evaluating brensocatib for moderate to severe hidradenitis suppurativa failed to meet its primary and secondary efficacy endpoints. As a result, Insmed will discontinue the development of brensocatib for this indication. Although the drug was well-tolerated and no new safety signals were found, the study's outcomes were disappointing, with lower reductions in abscess and inflammatory nodule counts compared to the placebo. Insights from this study may aid in advancing the scientific understanding of hidradenitis suppurativa.
Read more →About Insmed Incorporated
Headquarters700 US HIGHWAY 202/206, BRIDGEWATER, NJ, 08807
BIOPHARMAWATCH ELITE PLUS
Trade the next INSM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime